<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Neurol</journal-id>
      <journal-id journal-id-type="publisher-id">ana</journal-id>
      <journal-title-group>
        <journal-title>Annals of Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0364-5134</issn>
      <issn pub-type="epub">1531-8249</issn>
      <publisher>
        <publisher-name>BlackWell Publishing Ltd</publisher-name>
        <publisher-loc>Oxford, UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24272827</article-id>
      <article-id pub-id-type="pmc">4223934</article-id>
      <article-id pub-id-type="doi">10.1002/ana.24073</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>GRIN2B</italic> Mutations in West Syndrome and Intellectual Disability with
Focal Epilepsy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lemke</surname>
            <given-names>Johannes R</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au1">1</xref>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hendrickx</surname>
            <given-names>Rik</given-names>
          </name>
          <degrees>BSc</degrees>
          <xref ref-type="aff" rid="au3">3</xref>
          <xref ref-type="aff" rid="au4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Geider</surname>
            <given-names>Kirsten</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref ref-type="aff" rid="au5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laube</surname>
            <given-names>Bodo</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schwake</surname>
            <given-names>Michael</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harvey</surname>
            <given-names>Robert J</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>James</surname>
            <given-names>Victoria M</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pepler</surname>
            <given-names>Alex</given-names>
          </name>
          <degrees>MBiol</degrees>
          <xref ref-type="aff" rid="au7">7</xref>
          <xref ref-type="aff" rid="au8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Steiner</surname>
            <given-names>Isabelle</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref ref-type="aff" rid="au8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>H&#xF6;rtnagel</surname>
            <given-names>Konstanze</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neidhardt</surname>
            <given-names>John</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruf</surname>
            <given-names>Susanne</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wolff</surname>
            <given-names>Markus</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bartholdi</surname>
            <given-names>Deborah</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caraballo</surname>
            <given-names>Roberto</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Platzer</surname>
            <given-names>Konrad</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suls</surname>
            <given-names>Arvid</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="aff" rid="au3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Jonghe</surname>
            <given-names>Peter</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="aff" rid="au3">3</xref>
          <xref ref-type="aff" rid="au4">4</xref>
          <xref ref-type="aff" rid="au14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Biskup</surname>
            <given-names>Saskia</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="au8">8</xref>
          <xref ref-type="aff" rid="au11">11</xref>
          <xref ref-type="aff" rid="au15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weckhuysen</surname>
            <given-names>Sarah</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="aff" rid="au3">3</xref>
          <xref ref-type="aff" rid="au4">4</xref>
        </contrib>
        <aff id="au1">
          <label>1</label>
          <institution>Division of Human Genetics, University Children&#x2019;s
Hospital Inselspital</institution>
          <addr-line>Bern, Switzerland</addr-line>
        </aff>
        <aff id="au2">
          <label>2</label>
          <institution>Partners of EuroEPINOMICS, RES
consortium</institution>
        </aff>
        <aff id="au3">
          <label>3</label>
          <institution>Neurogenetics Group, Department of Molecular Genetics,
Vlaams Institute of Biotechnology</institution>
          <addr-line>Antwerp, Belgium</addr-line>
        </aff>
        <aff id="au4">
          <label>4</label>
          <institution>Laboratory of Neurogenetics, Institute Born-Bunge,
University of Antwerp</institution>
          <addr-line>Antwerp, Belgium</addr-line>
        </aff>
        <aff id="au5">
          <label>5</label>
          <institution>Department of Neurophysiology and Neurosensory Systems,
Technical University Darmstadt</institution>
          <addr-line>Darmstadt, Germany</addr-line>
        </aff>
        <aff id="au6">
          <label>6</label>
          <institution>Biochemistry III, Faculty of Chemistry, University of
Bielefeld</institution>
          <addr-line>Bielefeld, Germany</addr-line>
        </aff>
        <aff id="au7">
          <label>7</label>
          <institution>Department of Pharmacology, University College London
School of Pharmacy</institution>
          <addr-line>London, United Kingdom</addr-line>
        </aff>
        <aff id="au8">
          <label>8</label>
          <institution>CeGaT GmbH</institution>
          <addr-line>T&#xFC;bingen, Germany</addr-line>
        </aff>
        <aff id="au9">
          <label>9</label>
          <institution>Institute of Medical Molecular Genetics, University of
Zurich</institution>
          <addr-line>Switzerland</addr-line>
        </aff>
        <aff id="au10">
          <label>10</label>
          <institution>Department of Neuropediatrics, University of
T&#xFC;bingen</institution>
          <addr-line>T&#xFC;bingen, Germany</addr-line>
        </aff>
        <aff id="au11">
          <label>11</label>
          <institution>Institute of Clinical Genetics</institution>
          <addr-line>Klinikum Stuttgart, Stuttgart, Germany</addr-line>
        </aff>
        <aff id="au12">
          <label>12</label>
          <institution>Department of Neurology, Juan P. Garrahan Pediatric
Hospital</institution>
          <addr-line>Buenos Aires, Argentina</addr-line>
        </aff>
        <aff id="au13">
          <label>13</label>
          <institution>Department of Human Genetics, University of
L&#xFC;beck</institution>
          <addr-line>L&#xFC;beck, Germany</addr-line>
        </aff>
        <aff id="au14">
          <label>14</label>
          <institution>Department of Neurology, Antwerp University
Hospital</institution>
          <addr-line>Antwerp, Belgium</addr-line>
        </aff>
        <aff id="au15">
          <label>15</label>
          <institution>Hertie Institute of Clinical Brain Research and German
Center for Neurodegenerative Diseases, University of T&#xFC;bingen</institution>
          <addr-line>T&#xFC;bingen, Germany</addr-line>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address correspondence to Dr Lemke, University Children&#x2019;s Hospital,
Inselspital, CH-3010 Bern, Switzerland. E-mail: <email>johannes.lemke@insel.ch</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>02</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>75</volume>
      <issue>1</issue>
      <fpage>147</fpage>
      <lpage>154</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors. Annals of Neurology published by Wiley Periodicals,
Inc. on behalf of Child Neurology Society/American Neurological Association.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open access article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Objective</title>
          <p>To identify novel epilepsy genes using a panel approach and describe the functional consequences
of mutations.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Using a panel approach, we screened 357 patients comprising a vast spectrum of epileptic
disorders for defects in genes known to contribute to epilepsy and/or intellectual disability (ID).
After detection of mutations in a novel epilepsy gene, we investigated functional effects in
<italic>Xenopus laevis</italic> oocytes and screened a follow-up cohort.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We revealed de novo mutations in <italic>GRIN2B</italic> encoding the NR2B subunit of the
N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental
delay as well as 1 individual with ID and focal epilepsy. The patient with ID and focal epilepsy had
a missense mutation in the extracellular glutamate-binding domain (p.Arg540His), whereas both West
syndrome patients carried missense mutations within the NR2B ion channel-forming re-entrant loop
(p.Asn615Ile, p.Val618Gly). Subsequent screening of 47 patients with unexplained infantile spasms
did not reveal additional de novo mutations, but detected a carrier of a novel inherited
<italic>GRIN2B</italic> splice site variant in close proximity (c.2011-5_2011-4delTC). Mutations
p.Asn615Ile and p.Val618Gly cause a significantly reduced Mg<sup>2+</sup> block and higher
Ca<sup>2+</sup> permeability, leading to a dramatically increased Ca<sup>2+</sup>
influx, whereas p.Arg540His caused less severe disturbance of channel function, corresponding to the
milder patient phenotype.</p>
        </sec>
        <sec>
          <title>Interpretation</title>
          <p>We identified <italic>GRIN2B</italic> gain-of-function mutations as a cause of West syndrome with
severe developmental delay as well as of ID with childhood onset focal epilepsy. Severely disturbed
channel function corresponded to severe clinical phenotypes, underlining the important role of
facilitated NMDA receptor signaling in epileptogenesis.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p>Epileptic encephalopathies (EEs) constitute a group of disorders in which the epileptic activity
itself is considered to contribute to severe cognitive impairment or decline above and beyond what
might be expected from the underlying pathology alone.<xref rid="b1" ref-type="bibr">1</xref> West
syndrome belongs to this heterogeneous group of disorders presenting with distinctive clinical and
electrophysiological features usually manifesting between 3 and 12 months as clusters of infantile
spasms (IS) and a characteristic electroencephalogram (EEG) pattern called hypsarrhythmia.<xref rid="b2" ref-type="bibr">2</xref> The etiology of West syndrome is very diverse, and a substantial
subgroup is considered to have a genetic origin. West syndrome has been associated with mutations in
<italic>ARX</italic>, <italic>CDKL5</italic>, <italic>STXBP1</italic>, and <italic>ST3GAL3</italic>
as well as various copy number variations (CNVs).<xref rid="b3" ref-type="bibr">3</xref>&#x2013;<xref rid="b7" ref-type="bibr">7</xref> However, in many cases the genetic defect
remains unresolved.</p>
    <p>Mutations in <italic>GRIN2A</italic> and <italic>GRIN2B</italic> encoding the alpha and beta-2
subunits (NR2A and NR2B) of the glutamate-activated N-methyl-D-aspartate (NMDA) receptor are
associated with several neurodevelopmental disorders. Mutations in <italic>GRIN2A</italic> have
recently been detected in idiopathic focal epilepsy with rolandic spikes and related epileptic
encephalopathies, that is, in Landau&#x2013;Kleffner syndrome, epilepsy with continuous
spike-and-waves during slow sleep syndrome, and nonsyndromic epilepsy associated with intellectual
disability (ID).<xref rid="b8" ref-type="bibr">8</xref>&#x2013;<xref rid="b11" ref-type="bibr">11</xref> By contrast, <italic>GRIN2B</italic> has not been described as an epilepsy gene to date
but has repeatedly been considered as a putative candidate gene for seizures,<xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b12" ref-type="bibr">12</xref> and mutations were detected in patients
with ID, autism spectrum disorders (ASD), and schizophrenia.<xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b13" ref-type="bibr">13</xref>&#x2013;<xref rid="b18" ref-type="bibr">18</xref></p>
    <sec sec-type="materials|methods">
      <title>Materials and Methods</title>
      <p>We used a targeted massive parallel resequencing approach to diagnostically screen 357
individuals (Cohort A) with a broad range of epilepsy phenotypes. The panel contained 50 known genes
comprising EE genes, plus genes for severe ID not associated with seizures, but nevertheless
suspected to be involved in epileptogenesis (eg, voltage-sensitive and ligand-gated ion-channel
genes). Analysis was performed as described previously.<xref rid="b19" ref-type="bibr">19</xref>
Ninety-one of the 357 individuals were diagnosed with EE. Detailed clinical information necessary
for a more specific epilepsy syndrome classification was not available for many of these 91
patients. After detecting de novo mutations in <italic>GRIN2B</italic> within Cohort A, we
subsequently screened 47 patients with unexplained IS (Cohort B) by conventional methods. Three
patients were diagnosed with Ohtahara syndrome and 38 with West syndrome, and 6 patients had a
nonsyndromic early onset EE with IS during the course of the disease.</p>
      <sec>
        <title>Sequence Analysis</title>
        <p>We performed direct Sanger sequencing to detect point mutations/small indels as well as multiplex
amplicon quantification (MAQ) to detect CNVs in DNA extracted from peripheral blood. All 13 exons
and intron&#x2013;exon boundaries of <italic>GRIN2B</italic> were analyzed by bidirectional
sequencing with the BigDye Terminator v3.1 Cycle Sequencing kit on an ABI3730 DNA Analyzer (Applied
Biosystems, Foster City, CA; primers available upon request).</p>
        <p>Additionally, the genomic region containing <italic>GRIN2B</italic> was screened for CNVs by use
of an in-house&#x2013;developed technique for MAQ (<ext-link ext-link-type="uri" xlink:href="http://www.multiplicom.com/multiplex-amplicon-quantification-maq">http://www.multiplicom.com/multiplex-amplicon-quantification-maq</ext-link>) in Cohort B. This
assay comprises a multiplex polymerase chain reaction (PCR) amplification of fluorescently labeled
target and reference amplicons, followed by fragment analysis on the ABI3730 DNA Analyzer.<xref rid="b20" ref-type="bibr">20</xref> The comparison of normalized peak areas between the test
individual and the average of 5 control individuals results in the target amplicon doses indicating
the copy number of the target amplicon (using the in-house&#x2013;developed Multiplex Amplicon
Quantification Software; <ext-link ext-link-type="uri" xlink:href="http://www.multiplicom.com/maq-s">http://www.multiplicom.com/maq-s</ext-link>). The
multiplex PCR reaction consists of 10 test amplicons located in the genomic region of
<italic>GRIN2B</italic> and 6 reference amplicons randomly located on different chromosomes (primer
mix is available upon request).</p>
      </sec>
      <sec>
        <title>In Silico Prediction</title>
        <p>Pathogenic implications of identified coding variants were assessed by different in silico
analysis programs (PolyPhen2, <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link> and MutationTaster, <ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org">http://www.mutationtaster.org</ext-link>; Table <xref ref-type="table" rid="tbl1">1</xref>). For
intronic single nucleotide polymorphisms, splice site analysis was performed using HSF2.4 (<ext-link ext-link-type="uri" xlink:href="http://umd.be/HSF/">http://umd.be/HSF/</ext-link>).</p>
        <table-wrap id="tbl1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Mutations Detected in <italic>GRIN2B</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Patient</th>
                <th align="left" rowspan="1" colspan="1">Phenotype</th>
                <th align="left" rowspan="1" colspan="1">Mutation</th>
                <th align="left" rowspan="1" colspan="1">Prediction (MutationTaster/Polyphen-2)</th>
                <th align="left" rowspan="1" colspan="1">Origin</th>
                <th align="left" rowspan="1" colspan="1">Domain</th>
                <th align="left" rowspan="1" colspan="1">Functional Effect</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">West syndrome</td>
                <td align="left" rowspan="1" colspan="1">c.1853T&gt;G, p.Val618Gly</td>
                <td align="left" rowspan="1" colspan="1">Disease causing/damaging</td>
                <td align="left" rowspan="1" colspan="1">De novo</td>
                <td align="left" rowspan="1" colspan="1">Channel pore</td>
                <td align="left" rowspan="1" colspan="1">Gain of function</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">2</td>
                <td align="left" rowspan="1" colspan="1">West syndrome</td>
                <td align="left" rowspan="1" colspan="1">c.1844A&gt;T, p.Asn615Ile</td>
                <td align="left" rowspan="1" colspan="1">Disease causing/damaging</td>
                <td align="left" rowspan="1" colspan="1">De novo</td>
                <td align="left" rowspan="1" colspan="1">Channel pore</td>
                <td align="left" rowspan="1" colspan="1">Gain of function</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">3</td>
                <td align="left" rowspan="1" colspan="1">Focal epilepsy &amp; ID</td>
                <td align="left" rowspan="1" colspan="1">c.1619G&gt;A, p.Arg540His</td>
                <td align="left" rowspan="1" colspan="1">Disease causing/damaging</td>
                <td align="left" rowspan="1" colspan="1">De novo</td>
                <td align="left" rowspan="1" colspan="1">Glutamate-binding domain</td>
                <td align="left" rowspan="1" colspan="1">Gain of function (mild)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">West syndrome</td>
                <td align="left" rowspan="1" colspan="1">c.2011-5_2011-4delTC</td>
                <td align="left" rowspan="1" colspan="1">Not applicable</td>
                <td align="left" rowspan="1" colspan="1">Paternal</td>
                <td align="left" rowspan="1" colspan="1">Not applicable</td>
                <td align="left" rowspan="1" colspan="1">Potential splice defect</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>ID = intellectual disability.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The mutation of the ligand-binding domain in <italic>GRIN2B</italic> encoding human NR2B was
analyzed using the x-ray crystal structure<xref rid="b21" ref-type="bibr">21</xref> of rat NR2A
(Protein Data Bank # 2A5S). Rat NR2A and human NR2B share 82% sequence identity and
88% sequence similarity in their glutamate-binding regions, making the rat NR2A structure a
useful template for the analysis of mutations in <italic>GRIN2B</italic>. The interactive
visualization program University of California, San Francisco (UCSF) Chimera<xref rid="b22" ref-type="bibr">22</xref> was used for structural analysis. The &#x201C;swapaa&#x201D; command was used to
substitute amino acids, selecting the side chain from the Dunbrack backbone-dependent rotamer
library based on lowest number of clashes, highest number of hydrogen bonds, and highest
probability.</p>
        <p>Molecular modeling of the transmembrane domains of NR1/NR2B receptors was based on the crystal
structure of GluR2 (Brookhaven Protein Data Bank entry 3KG2) using Modeller 9v6 (UCSF Sali Lab) and
lsqman 9.7.9 (Uppsala Software Factory, Uppsala, Sweden) as described.<xref rid="b21" ref-type="bibr">21</xref> Models were subjected to short-term molecular dynamics simulations using the
Charmm27 force field, which is implemented in the Tinker 4.2 molecular modeling software (<ext-link ext-link-type="uri" xlink:href="http://dasher.wustl.edu/tinker/">http://dasher.wustl.edu/tinker/</ext-link>). Figures
were made using PyMOL 1.2 (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">http://www.pymol.org</ext-link>).</p>
      </sec>
      <sec>
        <title>Functional Investigations</title>
        <p>For <italic>Xenopus laevis</italic> oocyte experiments, NR1-1a and NR2B constructs and capped
cRNAs were generated as described previously.<xref rid="b8" ref-type="bibr">8</xref> Mutations were
introduced into these constructs using the QuikChange site-directed mutagenesis kit (Stratagene,
Agilent Technologies, Santa Clara, CA) and confirmed by Sanger DNA sequencing. Individual stage V to
VI oocytes were obtained from anaesthetized frogs and isolated by collagenase treatment. Ten
nanograms of total NR1/NR2B cRNA were injected into oocytes. Following injection, oocytes were kept
at 17&#xB0;C in ND96 solution (96mM NaCl, 2mM KCl, 1.8mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>,
5mM HEPES, pH 7.4). Glutamate and glycine dose&#x2013;response curves of wild-type NR1/NR2B and
mutant NMDA receptors were analyzed by 2-electrode voltage-clamp recording as described.<xref rid="b23" ref-type="bibr">23</xref> Concentration&#x2013;response curves and current traces shown in
the figures were drawn using KaleidaGraph (Synergy Software, Reading, PA). To monitor the voltage
dependence of NR1-NR2B receptor combinations, whole-cell current-voltage relationships of saturating
glutamate- and glycine-induced currents were recorded in 20mV intervals ranging from &#x2212;90mV to
+30mV and normalized to the current value obtained at +30mV above the respective
reversal potential as described previously.<xref rid="b24" ref-type="bibr">24</xref> The relative
divalent to monovalent permeability was calculated by the Goldman&#x2013;Hodgkin&#x2013;Katz
constant field voltage equation assuming no anion permeability. The internal concentrations of
Na<sup>+</sup> and K<sup>+</sup> used in the calculations were 20mM and 150mM,
respectively.<xref rid="b24" ref-type="bibr">24</xref> Permeability ratios were calculated for each
oocyte and then averaged. Mg<sup>2+</sup> inhibition (1mM) was evaluated in the presence of
1.8mM Ca<sup>2+</sup> at a holding potential of &#x2212;70mV upon application (5 seconds) of
saturating glycine (10&#x3BC;M) and glutamate (100&#x3BC;M) concentrations.</p>
      </sec>
      <sec>
        <title>Statistical Analyses</title>
        <p>Values given represent means &#xB1; standard error of the mean. Statistical significance was
determined at the <italic>p</italic> &lt; 0.05, <italic>p</italic> &lt; 0.01, and
<italic>p</italic> &lt; 0.001 levels using Student 2-tailed, unpaired <italic>t</italic>
test.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <sec>
        <title>Sequence Analysis and Functional Investigations</title>
        <p>Among the 357 patients of Cohort A, we identified 2 individuals with West syndrome (Patients 1
and 2) carrying novel heterozygous de novo mutations in <italic>GRIN2B</italic> (2 of 91 EE cases,
2.2%) affecting key amino acids (p.Val618Gly and p.Asn615Ile) within the NR2B ion
channel-forming re-entrant loop, as well as a patient with ID and childhood onset focal epilepsy
(Patient 3) carrying a novel heterozygous de novo mutation (p.Arg540His) within the NR2B
glutamate-binding domain (see Table, <xref ref-type="fig" rid="fig01">Fig 1</xref>).</p>
        <fig id="fig01" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Location of <italic>GRIN2B</italic> mutations in a schematic illustration of the conserved
domains of the NR2B subunit (SP = signal peptide; ATD = amino-terminal domain,
involved in receptor assembly; S1 and S2 form the ligand-binding domain; Pore = re-entrant
pore-forming and transmembrane spanning domains; PDZ = PDZ domain binding motif). All
reported de novo mutations and their according phenotypes (ASD = autism spectrum disorders;
FE = focal epilepsy; ID = intellectual disability; LGS = Lennox&#x2013;Gastaut
syndrome; Scz = schizophrenia) are listed in the top row. Mutations causing phenotypes
without seizures are labeled in black, mutations in epilepsy patients are in red. So far, no
pathogenic variants have been observed in the C-terminal region of NR2B. Mutations causing West
syndrome cluster within re-entrant pore-forming domain, whereas the mutation causing ID and focal
epilepsy was observed in the glutamate-binding domain S1, similar to a recently described LGS case.
Nonsynonymous variants that are believed not to be associated with abnormal phenotypes (gray) and
are reported more than once (in brackets) in the Exome Variant Server (EVS) are listed in the bottom
line.</p>
          </caption>
          <graphic xlink:href="ana0075-0147-f1"/>
        </fig>
        <p>Mutation p.Asn615Ile (Patient 2) affects 1 of 2 paired asparagines (Asn615, Asn616 in NR2B) in
the re-entrant pore-forming loop implicated in Mg<sup>2+</sup> block, and p.Val618Gly
(Patient 1) is in close vicinity. Expression of NR1/NR2B<sup>Asn615Ile</sup> and
NR1/NR2B<sup>Val618Gly</sup> heteromers revealed a significant loss of ion-channel block by
extracellular Mg<sup>2+</sup> and a dramatically increased Ca<sup>2+</sup>
permeability (<xref ref-type="fig" rid="fig02">Fig 2</xref>), consistent with a gain of function and
consequent hyperexcitability. By contrast, p.Arg540His (Patient 3) affects a highly conserved
residue located in the extracellular glutamate-binding region. Mutation of p.Arg540His is predicted
to abolish the hydrogen bonding with the backbone of Cys746 and His802, and a cation&#x2013;pi
interaction with His802, possibly leading to a relaxed fold in this region (<xref ref-type="fig" rid="fig03">Fig 3</xref>). Curiously, rather than affecting glutamate binding, p.Arg540His also
resulted in a decrease of Mg<sup>2+</sup> block and increase of Ca<sup>2+</sup>
permeability, implying an allosteric effect for this mutation. However, the functional impacts were
less severe, in line with the milder phenotype of the patient (see <xref ref-type="fig" rid="fig02">Fig 2</xref>).</p>
        <fig id="fig02" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Structural and functional consequences of missense mutations in <italic>GRIN2B</italic>.
(<bold>A</bold>) Topology model of an NR1 and an NR2B subunit. Positions of the alterations
p.Arg540His, p.Asn615Ile and p.Val618Gly are indicated by asterisks in the NR2 subunit consisting of
an amino-terminal domain (ATD), the ligand-binding domain (LBD) including the S1 and S2 peptide
segments, 3 transmembrane segments (M1, M2, and M3), a re-entrant pore loop (P), and an
intracellular carboxy-terminal domain (CTD). Residue Arg540 lies within the glutamate-binding
domain, and Asn615 and Val618 in the ion channel pore. N = NH<sub>2</sub>-terminus; C
= COOH-terminus. (<bold>B</bold>) Model of the transmembrane arrangement of the
N-methyl-D-aspartate (NMDA) receptor composed of NR1 (green) and NR2B (cyan) subunits (top view).
The arrow highlights the side chains of p.Asn615Ile and p.Val618Gly in the pore-forming region.
(<bold>C</bold>) Gradual loss of Mg<sup>2+</sup> inhibition of NR1-NR2B wild-type and
NR1-NR2B mutant receptor currents at &#x2212;70mV. Respective sample traces of NR1-NR2B and
NR1-NR2B<sup>Asn615Ile</sup> are shown above with inhibition of receptor currents by 1mM
Mg<sup>2+</sup> of NR1-NR2B (96 &#xB1; 0.9%, n=4) and mutant
NR1-NR2B<sup>Asn615Ile</sup> (14 &#xB1; 7.2%, <italic>p</italic> &lt; 0.0001, n
= 3), NR1-NR2B<sup>Val618Gly</sup> (48 &#xB1; 6.5%, <italic>p</italic> =
0.0003, n = 3), and NR1-NR2B<sup>Arg540His</sup> (81 &#xB1; 3.2%, <italic>p</italic>
= 0.005, n = 5) receptors. (<bold>D</bold>) Effect on Ca<sup>2+</sup>
permeability of NR1-NR2B wild-type and NR1-NR2B mutant receptor currents. Current&#x2013;voltage
relationships of NR1-NR2B receptors in the absence of Mg<sup>2+</sup> in
Na<sup>+</sup>-free extracellular solution reveal significant differences in the reversal
potential (indicated by <italic>arrows</italic>) of NR1-NR2B (&#x2212;31 &#xB1; 1.7mV, n =
4, <italic>black triangles</italic>) and mutant NR1-NR2B<sup>Asn615Ile</sup> (&#x2212;1.0 &#xB1;
6.8mV,<italic>p</italic> = 0.004, n = 3, <italic>red squares</italic>),
NR1-NR2B<sup>Val618Gly</sup> (&#x2212;5.4 &#xB1; 3.7mV, <italic>p</italic> &lt; 0.001, n
= 3, <italic>green squares</italic>), and NR1-NR2B<sup>Arg540His</sup> (&#x2212;9.4 &#xB1;
6.5mV, <italic>p</italic> = 0.013, n = 3, <italic>blue squares</italic>) receptor
currents. (NMDG-Cl, N-methyl-D-glucamine chloride) Calculation of the relative divalent to
monovalent cation permeability <italic>P</italic>Ca/<italic>P</italic>Na by the
Goldman&#x2013;Hodgkin&#x2013;Katz voltage equation revealed a &gt;3-fold increase in
Ca<sup>2+</sup> permeability of the mutant NMDA receptors
(<italic>P</italic>Ca/<italic>P</italic>Na for NR1-NR2B = 0.86; NR1-NR2B<sup>Asn615Ile</sup>
= 5.22; NR2B<sup>Val618Gly</sup> = 3.12; and NR2B<sup>Arg540His</sup> =
3.23).</p>
          </caption>
          <graphic xlink:href="ana0075-0147-f2"/>
        </fig>
        <fig id="fig03" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Structural and functional analyses of the glutamate binding-domain mutation Arg540His.
(<bold>A</bold>) Residue 540 is predicted to be located within the glutamate-binding S1 domain, and
is significant in the stabilization of the tertiary structure of the glutamate-binding domain.
(<bold>B</bold>) Substitution p.Arg540His is likely to abolish hydrogen bonding <italic>(blue
lines)</italic> with the backbone of Cys746 and His802 and a cation&#x2013;pi interaction with
His802, possibly leading to a relaxed fold in this region. (<bold>C</bold>) Pharmacological
characterization of the apparent agonist affinities of wild-type NR1-NR2B <italic>(black
triangles)</italic> and mutant NR1-NR2B<sup>Arg540His</sup>
<italic>(red squares)</italic> N-methyl-D-aspartate receptors measured after heterologous expression
in <italic>Xenopus laevis</italic> oocytes by 2-electrode voltage-clamping revealed that similar
glutamate concentrations were required to elicit half-maximal responses (EC<sub>50</sub> values
= 0.72 &#xB1; 0.22&#x3BC;M and 0.31 &#xB1; 0.02&#x3BC;M, respectively,
<italic>p</italic> = 0.14, n = 3). (D) Arg540 is a highly conserved residue within
NR2A&#x2013;D subunits.</p>
          </caption>
          <graphic xlink:href="ana0075-0147-f3"/>
        </fig>
        <p>Among the 47 patients of Cohort B, we detected 1 additional West syndrome patient (Patient 4)
with a novel paternally inherited heterozygous splice-site variant deleting 2 base pairs of the
splice acceptor site of exon 10, which encodes parts of the ion-channel pore domain of
<italic>GRIN2B</italic>. In silico prediction suggests a consecutive alternative splice acceptor
site 6 base pairs downstream of the mutated splice site that is only marginally weaker compared to
the wild-type splice acceptor site. Use of this alternative splice acceptor site is predicted to
result in an in-frame deletion of amino acids Phe671 and Gln672 (p.Phe671_Gln672del) of the
<italic>GRIN2B</italic> pore complex, which would be in line with the location of the mutations of
the 2 West syndrome patients described above. However, the latter putative splice variation was
inherited from the patient&#x2019;s healthy father, and no fresh sample or tissue was available to
functionally confirm the potentially aberrant splicing. Screening for copy number variations by MAQ
did not reveal additional deletions or duplications affecting <italic>GRIN2B</italic> in Cohort
B.</p>
      </sec>
      <sec>
        <title>Patient Phenotypes</title>
        <p>Patient 1 was a male born at term after an uneventful pregnancy. Myoclonic jerks and infantile
spasms occasionally occurring in clusters at the age of 4 months led to the diagnosis of West
syndrome. At 6 months old, he held no eye contact and presented with episodic hyperextension of
axial muscles. The result of first EEG was not available for review. EEG at age 8 months showed
multifocal bursts of irregular spike waves as well as rhythmic bilateral generalized spike waves
with a frequency of 4 to 5 per second reminiscent of modified hypsarrhythmia. During sleep, there
was rare irregular high-amplitude epileptiform activity with a hypsarrhythmialike pattern. Treatment
with vigabatrin and pyridoxine led to a slight clinical improvement. Replacement of vigabatrin by
levetiracetam improved neither seizures (predominantly of myoclonic type) nor EEG pattern, whereas
implementation of valproate finally led to a significant reduction of seizure frequency. At last
follow-up at age of 2 years and 1 month, the boy&#x2019;s length was at P90, weight at P25, and head
circumference at P50. He had severe axial hypotonia with episodic hyperextension and could not sit
independently. He could hold eye contact only briefly before drifting away. At this time, the boy
presented additionally with dystoniclike movements of his fingers and still had no verbal
communication.</p>
        <p>Patient 2 was a female born at term after an uneventful pregnancy. At the age of 7 weeks, she
presented with infantile spasms. She held no eye contact and showed muscular hypotonia. She had
episodic hyperextension of axial muscles. These episodes were not recorded on video EEG, and an
epileptic nature could not be excluded. Brain magnetic resonance imaging (MRI), magnetic resonance
spectroscopy, cerebrospinal investigation, and metabolic workup were normal. EEG showed typical
hypsarrhythmia. Treatment with vigabatrin, sulthiame, and topiramate failed to decrease seizures,
whereas implementation of steroid pulse therapy led to an improvement. At last follow-up at age 5
years and 3 months, the girl is not able to sit independently. She presented with autisticlike
behavior and no verbal expression, severe feeding difficulties, and mild microcephaly. The EEG
showed increased theta activity without epileptic discharges. The girl still exhibits series of
epileptic spasms as well as occasional generalized tonic&#x2013;clonic seizures.</p>
        <p>Patient 3 was a female born at 41 weeks after an uneventful pregnancy and conception by in vitro
fertilization. Early development was delayed, as she sat at 11 months, walked at 19 months, and used
her first words at 18 months. At the age of 3 years, she was diagnosed with global developmental
delay. There was no evidence for stagnation or even regression of development. Since the age of 9
years and 9 months she had focal dyscognitive seizures with postictal paresis of the right arm as
well as occasional bilateral convulsive seizures and status epilepticus. Postictal EEG showed
slowing over the left frontoparietal region, and MRI of the brain showed postictal diffusion
restriction in the same region that resolved over time. Lumbar puncture and metabolic screening were
normal. At the last follow-up at the age of 10 years and 6 months she had a mild intellectual
disability and occasional seizures with postictal paresis.</p>
        <p>Patient 4 was a male born at term after an uneventful pregnancy. At the age of 2 months epileptic
spasms occurred, which soon evolved into asymmetric tonic seizures. EEG at the age of 7 months
showed hypsarrhythmia, and multifocal epileptic activity was seen at the age of 14 months. MRI of
the brain, metabolic workup, and lumbar puncture were all normal. At last follow-up at the age of 4
years, he still had daily therapy-resistant tonic seizures and focal motor seizures. He had severe
intellectual disability with hypotonic muscle tone and was unable to talk or walk.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Our investigations revealed de novo <italic>GRIN2B</italic> missense mutations in 2 of 91
patients with unexplained EE (2.2%) and in 1 patient with ID and childhood onset focal
epilepsy. We also detected 1 novel inherited putative splice variant in 1 of 47 patients with IS.
The observation of a possibly reduced penetrance of an inherited splice variant in Patient 4 is in
agreement with previous observations<xref rid="b9" ref-type="bibr">9</xref> in families carrying
mutations and putative splice variants in <italic>GRIN2A</italic>. However, much larger data sets
are needed to prove a role of inherited <italic>GRIN2B</italic> variants as risk factors for these
disorders.</p>
      <p>Interestingly, the very recent study of the Epi4K consortium revealed 1 additional case of a de
novo mutation in <italic>GRIN2B</italic> in 1 of 115 individuals with epileptic encephalopathy of
Lennox&#x2013;Gastaut type (see <xref ref-type="fig" rid="fig01">Fig 1</xref>).<xref rid="b12" ref-type="bibr">12</xref> The patient shows parallels to Patient 3 of our present study. Both mutations
p.Arg540His (Patient 3) and p.Cys461Phe (Epi4K patient) are located in the extracellular
glutamate-binding region, and both patients presented with primary developmental delay and childhood
onset epilepsy.</p>
      <p>NMDA receptors are tetrameric ligand-gated ion channels permeable to Na<sup>+</sup>,
K<sup>+</sup>, and Ca<sup>2+</sup>, composed of 2 glycine-binding NR1 subunits and 2
glutamate-binding NR2 subunits (NR2A, NR2B, NR2C, NR2D).<xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref> Subunit composition of NMDA receptors is
spatially and temporally regulated with a switch from predominant NR2B expression in early
development to more prominent synaptically localized NR2A expression at later stages,<xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref> which might explain
the tendency toward earlier onset epilepsy phenotypes in <italic>GRIN2B</italic> versus
<italic>GRIN2A</italic> mutation carriers.</p>
      <p>NMDA receptor subunits are organized into multiple structural domains (see <xref ref-type="fig" rid="fig01">Fig 1</xref>) including a signal peptide, an amino-terminal domain involved in receptor
assembly, S1 and S2 segments that form the ligand binding domain, 3 membrane-spanning domains
M1&#x2013;M3, and a re-entrant pore-forming loop. Lastly, a large intracellular C-terminus and PDZ
domain-binding motif mediate interactions with intracellular proteins such as PSD95. In the Exome
Variant Server (EVS; National Heart, Lung, and Blood Institute Exome Sequencing Project, <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), 38
missense and no putative essential splice variants are listed in <italic>GRIN2B</italic> in 6503
healthy controls. The described variants are unevenly distributed, with the vast majority (27 of 38)
of variants being positioned within the NR2B C-terminus. Only 9 of 38 variants were detected
repeatedly, and again 7 of these are within the C-terminus. Curiously, the only described de novo
aberration within the NR2B C-terminus was detected in an apparently healthy control subject,<xref rid="b29" ref-type="bibr">29</xref> whereas all known pathogenic <italic>GRIN2B</italic> mutations
causing neurodevelopmental disorders are found within the N-terminal region, ligand-binding S1 and
S2 segments, and the re-entrant pore-forming loop (see <xref ref-type="fig" rid="fig01">Fig
1</xref>).<xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b13" ref-type="bibr">13</xref>&#x2013;<xref rid="b18" ref-type="bibr">18</xref> This suggests that pathogenic mutations
affecting key functional motifs have a greater impact on protein function and can negatively
influence neurodevelopment and brain excitability. This is also reflected by the finding that
variants outside the C-terminus of <italic>GRIN2B</italic> occurred significantly more frequently in
alleles of EE individuals of Cohorts A and B compared to the EVS controls (<italic>p</italic>
= 0.0027, Fisher exact test).</p>
      <p>Interestingly, 2 of the West syndrome patients presented gain-of-function mutations (Patient 1,
p.Val618Gly and Patient 2, p.Asn615Ile) in the re-entrant pore-forming loop. By contrast, Patient 3
with ID, childhood onset focal epilepsy, and less severe developmental delay carried a milder
gain-of-function mutation (p.Arg540His), positioned in the extracellular glutamate-binding S1
domain. Additionally, in support of the hypothesis that epilepsy is caused by gain-of-function
mutations in <italic>GRIN2B</italic>, truncating and thus predicted loss-of-function mutations have
only been described in patients with ID and/or ASD so far.<xref rid="b18" ref-type="bibr">18</xref>
These data suggest a distinct genotype&#x2013;phenotype correlation, although more mutations and
functional studies are needed to verify this assumption.</p>
      <p>In summary, we postulate that genetic alterations in <italic>GRIN2B</italic> are responsible for
&#x223C;2% (2 of 91) of EE cases, preferentially causing IS and West syndrome. This further
strengthens the concept that West syndrome comprises a heterogeneous group of several disease
entities, causing increased brain excitability with a similar and age-related EEG and seizure
pattern. Additionally, our findings reveal further evidence of the contribution of altered NMDA
receptor signaling to epileptogenesis and establish <italic>GRIN2B</italic> as another key player in
epileptic encephalopathies. In the patients described above, the severity of phenotypes corresponds
to the electrophysiological severity of gain of ion channel function. This is of particular interest
as existing NMDA receptor blockers such as memantine represent promising drugs to selectively
restore the altered NMDA receptor function in patients with gain-of-function mutations in NR2
subunits, putting NMDA receptors more in focus in the search for new targets in epilepsy
treatment.<xref rid="b30" ref-type="bibr">30</xref></p>
    </sec>
  </body>
  <back>
    <ack>
      <p>J.R.L. (32EP30_136042 / 1) and P.D.J. (G.A.136.11.N, FWO/ESF-ECRP) received financial support
within the EuroEPINOMICS-RES network (<ext-link ext-link-type="uri" xlink:href="http://www.euroepinomics.org">www.euroepinomics.org</ext-link>) within the Eurocores framework of the European Science
Foundation. R.J.H. received funding from the Medical Research Council (MR/J004049/1). S.B. received
further support from the Federal Ministry for Education and Research (IonNeurONet: 01GM1105A). M.S.
received financial support from the German Research Foundation (SFB877). A.S. received funding for a
postdoctoral fellowship by the Fonds Wetenschappelijk Onderzoek. We thank all patients and family
members for their participation in this study.</p>
    </ack>
    <sec>
      <title>Authorship</title>
      <p>S.B. and S.W. contributed equally to this work.</p>
    </sec>
    <sec>
      <title>Potential Conflicts of Interest</title>
      <p>J.R.L. and M.W.: expert testimony, CeGaT GmbH.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Berkovic</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Revised terminology and concepts for organization of seizures and epilepsies: report
of the ILAE Commission on Classification and Terminology, 2005&#x2013;2009</article-title>
          <source>Epilepsia</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>676</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">20196795</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Roger</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>Epileptic syndromes in infancy, childhood and adolescence</source>
          <year>2005</year>
          <publisher-loc>Montrouge, France</publisher-loc>
          <publisher-name>John Libbey Eurotext</publisher-name>
        </element-citation>
      </ref>
      <ref id="b3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stromme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mangelsdorf</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Scheffer</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Gecz</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in
Aristaless related homeobox gene, ARX</article-title>
          <source>Brain Dev</source>
          <year>2002</year>
          <volume>24</volume>
          <fpage>266</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="pmid">12142061</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalscheuer</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Donnelly</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile
spasms and mental retardation</article-title>
          <source>Am J Hum Genet</source>
          <year>2003</year>
          <volume>72</volume>
          <fpage>1401</fpage>
          <lpage>1411</lpage>
          <pub-id pub-id-type="pmid">12736870</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saitsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tohyama</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kumada</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe
cerebral hypomyelination, spastic quadriplegia, and developmental delay</article-title>
          <source>Am J Hum Genet</source>
          <year>2010</year>
          <volume>86</volume>
          <fpage>881</fpage>
          <lpage>891</lpage>
          <pub-id pub-id-type="pmid">20493457</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Edvardson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Muhlenhoff</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>West syndrome caused by ST3Gal-III deficiency</source>
          <year>2013</year>
          <volume>54</volume>
          <publisher-name>Epilepsia</publisher-name>
          <fpage>e24</fpage>
          <lpage>e27</lpage>
        </element-citation>
      </ref>
      <ref id="b7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paciorkowski</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Thio</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Copy number variants and infantile spasms: evidence for abnormalities in ventral
forebrain development and pathways of synaptic function</article-title>
          <source>Eur J Hum Genet</source>
          <year>2011</year>
          <volume>19</volume>
          <fpage>1238</fpage>
          <lpage>1245</lpage>
          <pub-id pub-id-type="pmid">21694734</pub-id>
        </element-citation>
      </ref>
      <ref id="b8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Endele</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosenberger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Geider</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause
variable neurodevelopmental phenotypes</article-title>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>1021</fpage>
          <lpage>1026</lpage>
          <pub-id pub-id-type="pmid">20890276</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lemke</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Lal</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Reinthaler</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic
spikes</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>1067</fpage>
          <lpage>1072</lpage>
          <pub-id pub-id-type="pmid">23933819</pub-id>
        </element-citation>
      </ref>
      <ref id="b10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvill</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Yendle</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>GRIN2A mutations cause epilepsy-aphasia spectrum disorders</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>1073</fpage>
          <lpage>1076</lpage>
          <pub-id pub-id-type="pmid">23933818</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lesca</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rudolf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bruneau</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies
and encephalopathies with speech and language dysfunction</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>1061</fpage>
          <lpage>1066</lpage>
          <pub-id pub-id-type="pmid">23933820</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <element-citation publication-type="journal">
          <collab>Epi4K Consortium; Epilepsy Phenome/Genome Project</collab>
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Berkovic</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Cossette</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo mutations in epileptic encephalopathies</article-title>
          <source>Nature</source>
          <year>2013</year>
          <volume>501</volume>
          <fpage>217</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="pmid">23934111</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Ligt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Willemsen</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>van Bon</surname>
              <given-names>BW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic exome sequencing in persons with severe intellectual
disability</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <fpage>1921</fpage>
          <lpage>1929</lpage>
          <pub-id pub-id-type="pmid">23033978</pub-id>
        </element-citation>
      </ref>
      <ref id="b14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freunscht</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Popp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Blank</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Behavioral phenotype in five individuals with de novo mutations within the GRIN2B
gene</article-title>
          <source>Behav Brain Funct</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>20</fpage>
          <pub-id pub-id-type="pmid">23718928</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Roak</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Deriziotis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe de novo
mutations</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>585</fpage>
          <lpage>589</lpage>
          <pub-id pub-id-type="pmid">21572417</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Roak</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Vives</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum
disorders</article-title>
          <source>Science</source>
          <year>2012</year>
          <volume>338</volume>
          <fpage>1619</fpage>
          <lpage>1622</lpage>
          <pub-id pub-id-type="pmid">23160955</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tarabeux</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kebir</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum
disorders and schizophrenia</article-title>
          <source>Transl Psychiatry</source>
          <year>2011</year>
          <volume>1</volume>
          <fpage>e55</fpage>
          <pub-id pub-id-type="pmid">22833210</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kenny</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Cormican</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Furlong</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and
autism spectrum disorders</article-title>
          <source>Mol Psychiatry</source>
          <comment>2013 Oct 15. doi: <ext-link ext-link-type="doi" xlink:href="10.1038/mp.2013.127">10.1038/mp.2013.127</ext-link>. [Epub ahead of
print]</comment>
        </element-citation>
      </ref>
      <ref id="b19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lemke</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Riesch</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Scheurenbrand</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeted next generation sequencing as a diagnostic tool in epileptic
disorders</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>1387</fpage>
          <lpage>1398</lpage>
          <pub-id pub-id-type="pmid">22612257</pub-id>
        </element-citation>
      </ref>
      <ref id="b20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suls</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Claeys</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Goossens</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI
patients</article-title>
          <source>Hum Mutat</source>
          <year>2006</year>
          <volume>27</volume>
          <fpage>914</fpage>
          <lpage>920</lpage>
          <pub-id pub-id-type="pmid">16865694</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furukawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Mancusso</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gouaux</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Subunit arrangement and function in NMDA receptors</article-title>
          <source>Nature</source>
          <year>2005</year>
          <volume>438</volume>
          <fpage>185</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="pmid">16281028</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettersen</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Goddard</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>CC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>UCSF Chimera&#x2014;a visualization system for exploratory research and
analysis</article-title>
          <source>J Comput Chem</source>
          <year>2004</year>
          <volume>25</volume>
          <fpage>1605</fpage>
          <lpage>1612</lpage>
          <pub-id pub-id-type="pmid">15264254</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laube</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sturgess</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis
of the glutamate binding site on the NR2B subunit</article-title>
          <source>Neuron</source>
          <year>1997</year>
          <volume>18</volume>
          <fpage>493</fpage>
          <lpage>503</lpage>
          <pub-id pub-id-type="pmid">9115742</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madry</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Laube</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Potentiation of glycine-gated NR1/NR3A NMDA receptors relieves Ca-dependent outward
rectification</article-title>
          <source>Front Mol Neurosci</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>6</fpage>
          <pub-id pub-id-type="pmid">20407581</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paoletti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bellone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity
and disease</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>383</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">23686171</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laube</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kuhse</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Evidence for a tetrameric structure of recombinant NMDA receptors</article-title>
          <source>J Neurosci</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>2954</fpage>
          <lpage>2961</lpage>
          <pub-id pub-id-type="pmid">9526012</pub-id>
        </element-citation>
      </ref>
      <ref id="b27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paoletti</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of NMDA receptor functional diversity</article-title>
          <source>Eur J Neurosci</source>
          <year>2011</year>
          <volume>33</volume>
          <fpage>1351</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">21395862</pub-id>
        </element-citation>
      </ref>
      <ref id="b28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hardingham</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Bading</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Synaptic versus extrasynaptic NMDA receptor signalling: implications for
neurodegenerative disorders</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>682</fpage>
          <lpage>696</lpage>
          <pub-id pub-id-type="pmid">20842175</pub-id>
        </element-citation>
      </ref>
      <ref id="b29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wieczorek</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Graf</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Range of genetic mutations associated with severe non-syndromic sporadic intellectual
disability: an exome sequencing study</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>380</volume>
          <fpage>1674</fpage>
          <lpage>1682</lpage>
          <pub-id pub-id-type="pmid">23020937</pub-id>
        </element-citation>
      </ref>
      <ref id="b30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghasemi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schachter</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>The NMDA receptor complex as a therapeutic target in epilepsy: a
review</article-title>
          <source>Epilepsy Behav</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>617</fpage>
          <lpage>640</lpage>
          <pub-id pub-id-type="pmid">22056342</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
